Which has preferable earnings & valuation, CDRE or CLPT?

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadre $610.31M 1.96 $44.14M $0.89 31.46 ClearPoint Neuro $36.97M 14.99 -$25.54M -$1.01 N/A

Is CDRE or CLPT more profitable?

Cadre has a net margin of 5.80% compared to ClearPoint Neuro's net margin of -71.57%. Cadre's return on equity of 12.39% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Cadre 5.80% 12.39% 5.08% ClearPoint Neuro -71.57% -140.96% -36.98%

ClearPoint Neuro (CLPT) Competitors

$18.48 +0.52 (+2.90%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$18.40 -0.08 (-0.43%)

As of 06/26/2026 07:41 PM Eastern

Compare

CLPT vs. EYE, PRCT, BFLY, CDRE, and BLFS

Should you buy ClearPoint Neuro stock or one of its competitors? MarketBeat compares ClearPoint Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ClearPoint Neuro include National Vision (EYE), PROCEPT BioRobotics (PRCT), Butterfly Network (BFLY), Cadre (CDRE), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry.

How does ClearPoint Neuro compare to National Vision?

ClearPoint Neuro (NASDAQ:CLPT) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

ClearPoint Neuro currently has a consensus target price of $23.00, suggesting a potential upside of 24.46%. National Vision has a consensus target price of $30.08, suggesting a potential upside of 59.51%. Given National Vision's stronger consensus rating and higher possible upside, analysts plainly believe National Vision is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

National Vision has a net margin of 2.31% compared to ClearPoint Neuro's net margin of -71.57%. National Vision's return on equity of 6.41% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
National Vision	2.31%	6.41%	2.81%

In the previous week, ClearPoint Neuro had 1 more articles in the media than National Vision. MarketBeat recorded 3 mentions for ClearPoint Neuro and 2 mentions for National Vision. National Vision's average media sentiment score of 0.82 beat ClearPoint Neuro's score of -0.38 indicating that National Vision is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
National Vision	Positive

30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 2.4% of National Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

National Vision has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	14.99	-$25.54M	-$1.01	N/A
National Vision	$1.99B	0.76	$29.60M	$0.57	33.09

ClearPoint Neuro has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, National Vision has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

National Vision beats ClearPoint Neuro on 11 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

ClearPoint Neuro (NASDAQ:CLPT) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 3 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.72 beat ClearPoint Neuro's score of -0.38 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
PROCEPT BioRobotics	Very Positive

ClearPoint Neuro currently has a consensus target price of $23.00, suggesting a potential upside of 24.46%. PROCEPT BioRobotics has a consensus target price of $40.42, suggesting a potential upside of 79.15%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

PROCEPT BioRobotics has a net margin of -31.82% compared to ClearPoint Neuro's net margin of -71.57%. PROCEPT BioRobotics' return on equity of -27.70% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ClearPoint Neuro has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

ClearPoint Neuro has higher earnings, but lower revenue than PROCEPT BioRobotics. ClearPoint Neuro is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	14.99	-$25.54M	-$1.01	N/A
PROCEPT BioRobotics	$308.05M	4.17	-$95.57M	-$1.82	N/A

Summary

PROCEPT BioRobotics beats ClearPoint Neuro on 11 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and ClearPoint Neuro (NASDAQ:CLPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Butterfly Network had 9 more articles in the media than ClearPoint Neuro. MarketBeat recorded 12 mentions for Butterfly Network and 3 mentions for ClearPoint Neuro. Butterfly Network's average media sentiment score of 0.32 beat ClearPoint Neuro's score of -0.38 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Overall Sentiment
Butterfly Network	Neutral
ClearPoint Neuro	Neutral

ClearPoint Neuro has a net margin of -71.57% compared to Butterfly Network's net margin of -73.63%. Butterfly Network's return on equity of -34.41% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Butterfly Network has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Butterfly Network currently has a consensus price target of $5.56, suggesting a potential downside of 36.82%. ClearPoint Neuro has a consensus price target of $23.00, suggesting a potential upside of 24.46%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ClearPoint Neuro has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	22.97	-$77.06M	-$0.30	N/A
ClearPoint Neuro	$36.97M	14.99	-$25.54M	-$1.01	N/A

Summary

Butterfly Network beats ClearPoint Neuro on 11 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Cadre?

Cadre (NYSE:CDRE) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Cadre has a net margin of 5.80% compared to ClearPoint Neuro's net margin of -71.57%. Cadre's return on equity of 12.39% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	1.96	$44.14M	$0.89	31.46
ClearPoint Neuro	$36.97M	14.99	-$25.54M	-$1.01	N/A

In the previous week, Cadre had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 4 mentions for Cadre and 3 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 0.21 beat ClearPoint Neuro's score of -0.38 indicating that Cadre is being referred to more favorably in the media.

Company	Overall Sentiment
Cadre	Neutral
ClearPoint Neuro	Neutral

Cadre has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

44.0% of Cadre shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 30.1% of Cadre shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cadre currently has a consensus price target of $39.75, indicating a potential upside of 41.99%. ClearPoint Neuro has a consensus price target of $23.00, indicating a potential upside of 24.46%. Given Cadre's stronger consensus rating and higher probable upside, equities analysts plainly believe Cadre is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cadre beats ClearPoint Neuro on 16 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to BioLife Solutions?

ClearPoint Neuro (NASDAQ:CLPT) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

In the previous week, ClearPoint Neuro had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for ClearPoint Neuro and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.17 beat ClearPoint Neuro's score of -0.38 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
BioLife Solutions	Positive

BioLife Solutions has higher revenue and earnings than ClearPoint Neuro. BioLife Solutions is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	14.99	-$25.54M	-$1.01	N/A
BioLife Solutions	$96.21M	14.55	-$4.59M	-$0.08	N/A

ClearPoint Neuro currently has a consensus target price of $23.00, indicating a potential upside of 24.46%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 11.67%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ClearPoint Neuro has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

BioLife Solutions has a net margin of -2.80% compared to ClearPoint Neuro's net margin of -71.57%. BioLife Solutions' return on equity of 1.81% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
BioLife Solutions	-2.80%	1.81%	1.65%

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioLife Solutions beats ClearPoint Neuro on 11 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$554.21M	$7.36B	$7.04B	$12.18B
Dividend Yield	N/A	1.24%	2.66%	6.24%
P/E Ratio	-18.30	51.24	25.90	24.17
Price / Sales	14.99	81.77	600.60	118.47
Price / Cash	N/A	26.44	47.95	55.62
Price / Book	18.67	7.53	10.78	6.36
Net Income	-$25.54M	$159.20M	$3.58B	$337.99M
7 Day Performance	4.00%	1.80%	2.22%	0.10%
1 Month Performance	50.98%	-2.72%	-0.09%	-1.28%
1 Year Performance	56.61%	5.96%	34.39%	27.68%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	2.0346 of 5 stars	$18.48 +2.9%	$23.00 +24.5%	+56.6%	$554.21M	$36.97M	N/A	110	Gap Down
EYE National Vision	3.7812 of 5 stars	$17.96 -3.5%	$30.08 +67.5%	-18.6%	$1.49B	$1.99B	31.51	13,138	Positive News
PRCT PROCEPT BioRobotics	3.2365 of 5 stars	$23.22 -9.6%	$41.36 +78.1%	-60.4%	$1.46B	$308.05M	N/A	430	Analyst Upgrade High Trading Volume
BFLY Butterfly Network	1.3137 of 5 stars	$5.63 +1.5%	$5.56 -1.1%	+352.6%	$1.41B	$97.61M	N/A	460	News Coverage
CDRE Cadre	4.2243 of 5 stars	$29.08 -4.5%	$39.75 +36.7%	-12.6%	$1.30B	$610.31M	32.67	2,533	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. EYE, PRCT, BFLY, CDRE, and BLFS

How does ClearPoint Neuro compare to National Vision?

Summary

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

Summary

How does ClearPoint Neuro compare to Butterfly Network?

Summary

How does ClearPoint Neuro compare to Cadre?

Summary

How does ClearPoint Neuro compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. EYE, PRCT, BFLY, CDRE, and BLFS

How does ClearPoint Neuro compare to National Vision?

Do analysts rate CLPT or EYE?

Is CLPT or EYE more profitable?

Does the media refer more to CLPT or EYE?

Do institutionals & insiders hold more shares of CLPT or EYE?

Which has better valuation & earnings, CLPT or EYE?

Which has more risk & volatility, CLPT or EYE?

Summary

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

Does the media refer more to CLPT or PRCT?

Do analysts recommend CLPT or PRCT?

Is CLPT or PRCT more profitable?

Do insiders and institutionals have more ownership in CLPT or PRCT?

Which has more risk and volatility, CLPT or PRCT?

Which has preferable valuation & earnings, CLPT or PRCT?

Summary

How does ClearPoint Neuro compare to Butterfly Network?

Does the media favor BFLY or CLPT?

Is BFLY or CLPT more profitable?

Which has more risk and volatility, BFLY or CLPT?

Do analysts rate BFLY or CLPT?

Do insiders and institutionals hold more shares of BFLY or CLPT?

Which has better valuation & earnings, BFLY or CLPT?

Summary

How does ClearPoint Neuro compare to Cadre?

Is CDRE or CLPT more profitable?

Which has preferable earnings & valuation, CDRE or CLPT?

Does the media prefer CDRE or CLPT?

Which has more volatility and risk, CDRE or CLPT?

Do insiders and institutionals believe in CDRE or CLPT?

Do analysts rate CDRE or CLPT?

Summary

How does ClearPoint Neuro compare to BioLife Solutions?

Does the media favor CLPT or BLFS?

Which has stronger valuation & earnings, CLPT or BLFS?

Do analysts recommend CLPT or BLFS?

Which has more volatility & risk, CLPT or BLFS?

Is CLPT or BLFS more profitable?

Do insiders & institutionals believe in CLPT or BLFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools